Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.542    0.002 (0.37%)
Bid:
0.542
Ask:
0.648
Spread: 0.106 (19.557%)
Market Cap: £3.15m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Placing

12 Nov 2009 07:00

RNS Number : 3824C
Futura Medical PLC
12 November 2009
 



For immediate release 

12 November 2009

Futura Medical plc

("Futura" or "the Company")

Placing

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce a Placing by Nomura Code Securities Limited in which gross proceeds of £1.46 million are being raised through the issue of 4,864,471 new ordinary shares of 0.2 pence each in Futura ("Ordinary Shares"), to new and existing institutional and other investors at a price of 30 pence per share The Placing represents approximately 7.8% of the Company's issued share capital.

The net proceeds of the fundraising will be used to provide additional working capital, to support the regulatory approval of CSD500, to progress the Company's developmental projects, as well as to evaluate some early stage research leads. Further it is expected a strengthened balance sheet will assist in the Company's out-licensing negotiations with pharmaceutical and other partners. 

The Ordinary Shares will rank pari passu with the existing ordinary shares of the Company. Application has been made to the London Stock Exchange and it is anticipated that trading of the Ordinary Shares will commence on AIM at 8:00am on 18 November 2009. 

Futura's total issued shared capital following the admission of the Ordinary Shares will be 67,483,311. The total number of voting rights in the Company will be 67,483,311.

James Barder, Futura's Chief Executive, said: "We are pleased with the support of new and existing investors in this Placing, which will allow us to progress our exciting pipeline of products and give us the ability to capture more of their long term value. We continue to manage our costs carefully and intend to exploit our low cost business model to progress those projects that we believe have significant upside. Having a strengthened balance sheet will undoubtedly be of assistance in our current out-licensing discussions."

For any further information please contact:

Futura Medical plc

James Barder, Chief Executive

Tel: +44 (0) 1483 685 670

mail to: james.barder@futuramedical.co.uk

www.futuramedical.co.uk 

Nomura Code Securities Limited 

Charles Walker / Giles Balleny

Tel:+44 (0)20 7776 1200

For media enquiries please contact: 

Buchanan Communications

Mark Court / Stasa Filiplic / Jennie Spivey

Tel: +44 (0) 20 7466 5000

 

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEKFLFFKFBFFBQ
Date   Source Headline
11th Jan 201712:20 pmRNSDirector's Dealings
10th Jan 201712:40 pmRNSNED Remuneration and Total Voting Rights
10th Jan 20177:00 amRNSSigns UK Licensing Agreement in Pain Relief
5th Jan 20177:00 amRNSInitial Launch of CSD500 in MENA
28th Nov 20165:30 pmRNSCorrection: Notification of Major Interests
28th Nov 201612:00 pmRNSNotification of Major Interest in Shares
25th Nov 20165:25 pmRNSCorrection - Block Listing Update
25th Nov 20163:05 pmRNSBlock Listing Update
25th Nov 20169:30 amRNSNotification Of Major Interest In Shares
23rd Nov 20163:30 pmRNSNotification of Major Interest in Shares
16th Nov 20167:00 amRNSKen James to lead Futura's R&D
16th Nov 20167:00 amRNSMED2002 Update
15th Nov 20163:38 pmRNSResult of General Meeting
27th Oct 201612:45 pmRNSResult of Placing
27th Oct 20169:48 amRNSClose of Accelerated Bookbuild
27th Oct 20167:01 amRNSProposed Accelerated Bookbuild
27th Oct 20167:00 amRNSCSD500: Approval of TTK with Extended Shelf Life
13th Sep 20167:00 amRNSInterim Results
12th Sep 20165:45 pmRNSNotification of Major Interest in Shares
12th Sep 20163:00 pmRNSNotification of Major Interest in Shares
7th Sep 20167:00 amRNSMED2002: Breakthrough Results in $5 billion Market
25th Jul 20167:00 amRNSNotification of Half Year Results
21st Jun 20165:30 pmRNSResult of AGM
21st Jun 20167:00 amRNSAGM Statement
20th Jun 20167:00 amRNSLicenses CSD500 to Milsing for Southeast Europe
13th Jun 20167:00 amRNSManufacturing and Distribution Agreements with TTK
19th May 20164:30 pmRNSBlock Listing Update
4th May 20167:00 amRNSRecruitment Closes in MED2002 Study
26th Apr 201611:39 amRNSNotice of AGM
15th Mar 20167:00 amRNSPreliminary Results
7th Mar 20167:00 amRNSAppointment of Non-Executive Director
26th Feb 201612:00 pmRNSNotification of Major Interest in Shares
26th Jan 20167:00 amRNSCapital Markets Event
20th Jan 20167:00 amRNSCapital Markets Event
18th Jan 20162:33 pmRNSNotice of Preliminary Results
4th Jan 20161:15 pmRNSRemuneration of Non-Executive Directors
16th Dec 20157:00 amRNSExtends Shelf Life of CSD500
1st Dec 201510:13 amRNSNotification of Major Interest in Shares
24th Nov 20157:00 amRNSPositive Regulatory Update on Pain Portfolio
23rd Nov 20153:42 pmRNSBlocklisting Interim Review
23rd Nov 20153:18 pmRNSBlock Listing Update
17th Nov 20157:00 amRNSMED2002 Clinical Trial Update
23rd Oct 20157:00 amRNSNHS Reimbursement for MED2002 as a Special
14th Oct 20157:00 amRNSLicensing Agreement for MED2002
9th Oct 20157:30 amRNSNotification of Major Interest in Shares
10th Sep 20157:00 amRNSGrant of Options
9th Sep 20157:00 amRNSInterim Results
19th Aug 20153:15 pmRNSNotification of Major Interest in Shares
19th Aug 20157:00 amRNSNotice of Interim Results
16th Jul 20154:23 pmRNSNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.